2QV Stock Chart & Stats
€2.94
€0.00(0.00%)
At close: 4:00 PM EDT
€2.94
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.94 - €3.14
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.13M
Enterprise Value€6.28
Total Cash (Recent Filing)€6.69M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 06, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding7,200,378
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.32Price Target Upside46.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet LeverageMinimal debt lowers solvency risk and preserves financial flexibility while Chemomab advances clinical programs. This provides a stronger base for future financing or partnering than a similarly loss-making biotech carrying significant liabilities.
Improving Losses And Cash BurnNarrower losses and reduced cash burn indicate some expense discipline in the R&D operation. Although the company remains unprofitable, sustained cost control could extend the usefulness of available capital as clinical development continues.
Strategic Merger And Capital RunwayThe announced combination could materially strengthen Chemomab’s strategic position by adding Scipher’s precision-medicine capabilities, potential commercial revenue and committed funding. The planned AI-guided clinical strategy may improve development focus and financing visibility.
Bears Say
Pre-Revenue Business ModelWithout product revenue, the company has no recurring commercial cash inflow to fund research, trials or corporate expenses. Its fundamental value therefore remains dependent on clinical progress, regulatory success and eventual partnering or commercialization.
Persistent Cash-Burn And Financing DependenceOngoing negative operating and free cash flow means Chemomab cannot currently self-fund development. Continued dependence on equity or other external financing creates dilution risk and could constrain programs if access to capital becomes less favorable.
Declining Assets And EquityThe contraction in assets and shareholders’ equity reflects continued losses and cash usage, reducing the financial cushion available for clinical execution. The first-half 2026 net loss of $3.9 million reinforces the risk of further capital needs.
Chemomab Therapeutics News
2QV FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was €2.94 and its highest was €3.14 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is €16.13M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 52 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Aug 19, 2026. The company reported -€0.003 earnings per share for the quarter, beating the consensus estimate of -€0.128 by €0.126.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,200,378 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -€0.003 in its last earnings report, beating expectations of -€0.128. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in DE:2QV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
2QV Stock 12 Month Forecast
Average Price Target
€4.32
▲(46.78% Upside)